SYNERGY-NASH: Tirzepatide and metabolic steatohepatitis (MASH) SYNERGY-NASH (Loomba et al., NEJM 2024, NEJMoa2401943, PMID 38856224) is a phase 2 trial in 190 patients with metabolic steatohepatitis (MASH) and biopsy-proven stage 2 or 3 fibrosis
While scientific evidence for its efficacy in these applications is sparse and contentious, some people report improved skin tone and pigmentation after taking glutathione supplements or therapies
The losses in commercial masa increased significantly with prebake masa holding time
In contrast, dietary LCFAs drive nave T cell polarization toward Th17 cells through p38 MAPK signaling, aggravating pathology in experimental autoimmune encephalomyelitis (9698)
IGF-1 Blood Test: Why Peptide Therapy Should Never Start Without One An IGF-1 blood test is the lab value that tells a provider whether a growth hormone axis peptide is actually working
During its catalytic cycle, GDH shifts from an open conformation (the catalytic pocket, with binding sites for glutamate and NADH, is open) to a closed conformation (the catalytic pocket is closed, and the reaction can take place)
